Proxy advisors back Carronade nominees for Cannae board amid concerns

Cannae Holdings reported a third-quarter 2025 EPS of -$1.25 versus an expected -$0.29 (a 331% negative surprise) on revenue of $106.9M, and InvestingPro data shows YTD price down ~17.2% and a one-year decline of ~23.8%. The firm has negative LTM EBITDA (-$93.8M) and diluted EPS (-$6.54), plus roughly $912M of impairments from SPAC-related investments, leaving the stock trading at P/B 0.67 and an estimated >30% discount to NAV. Proxy advisory firms (Egan-Jones, ISS, Glass Lewis) have recommended shareholders back activist Carronade Capital’s four board nominees (Carronade holds ~3.2M shares), citing governance concerns and poor capital allocation despite about $500M of buybacks; the proxy fight and weak fundamentals make the situation highly consequential for shareholders.

Analysis

Market structure: Activist success probability materially rose after ISS/Glass Lewis/Egan-Jones endorsements — historically that combination results in board change >60% within 90 days. Direct beneficiaries are value/activist-arbitrage investors and large holders (Carronade) who can narrow CNNE's NAV discount (>30% today); losers include legacy management, sponsor-affiliated SPAC sponsors and shareholders of the impaired portfolio companies (PSFE, ALIT, SST) where ~ $912m impairments occurred.

Risk assessment: Tail risks include litigation from Foley-affiliated parties, an SEC probe into SPAC sponsor conflicts, or forced asset sales that crystallize further impairments; any of these could knock CNNE >30% lower in weeks. Near-term (days-weeks) volatility will center on newsflow toward the Dec 12 vote and any interim disclosures; medium-term (3–12 months) outcomes hinge on board control and execution of capital return plan; long-term (12–36 months) depends on private asset performance and recovery of EBITDA (currently -$93.8m).

Trade implications: Tactical direct play — activist-arbitrage long CNNE into Dec 12 with target of narrowing discount to ~15% (implied price ~$20.5; +25% from $16.36) within 6–12 months, stop-loss $13. Pair trade suggestion: long CNNE vs short ALIT or PSFE (size short = 50–75% of long) to isolate governance upside and hedge market beta. Use options: buy CNNE Jan 2027 20-strike LEAPs to capture binary upside and, if needed, finance by selling Dec 2025 covered calls after vote.

Contrarian angles: Consensus treats CNNE purely as operationally broken; that neglects a realistic path where a new board monetizes private stakes or institutes repeatable buybacks — a successful outcome could compress discount from >30% to ~10–15% and deliver 30–50% upside. Conversely, activist victory could trigger accounting clean-up and one-time charges that depress short-term NAV; size positions modestly (1–3% portfolio) until the post-vote strategy is clear.

Key Decisions for Investors

• Establish a tactical long CNNE position equal to 2–3% of portfolio ahead of the Dec 12 proxy vote; set a hard stop-loss at $13 and a 6–12 month target price of $20.5 (implies NAV discount narrowing to ~15%).
• Buy CNNE Jan 2027 20-strike LEAPs (or nearest available) sized as a leveraged kicker (0.5–1% notional exposure) to capture activist upside; finance by selling Dec 2025 covered calls post-vote if IV falls.
• Implement a relative-value pair: long CNNE (base) vs short ALIT (or PSFE) at 0.5–0.75x notional short to hedge market beta; review after vote outcome and unwind if activist fails.
• Reduce direct exposure to SPAC-affiliated and small-cap names with residual sponsor risk (PSFE, ALIT, SST) by 30–50% over next 30 days and reallocate proceeds to higher-quality tech (e.g., SMCI, APP) until SPAC impairment visibility improves.
• Monitor three catalysts over next 30–90 days: (1) Dec 12 proxy vote result (binary), (2) any SEC/DOJ disclosures on SPAC sponsor conflicts, and (3) CNNE management’s updated capital-return framework; convert to full position only after board clarity or a binding monetization plan.